Marcel Nijland
dr.
I work as a hematologist and my main focus is on patients with aggressive B-cell lymphomas and CNS lymphomas. My research is centered on the application of novel diagnostic and therapeutic strategies into clinical trials. These include imaging-studies like 18F-FDG-PET, Zr-Brentuximab-PET and Zr-atezolizumab-PET. In addition, I aim to implement novel strategies to measure minimal residual disease, and prognostic gene expression profiles in DLBCL. Linked to this I also focus on mutational analysis to study clonal evolution and prognostic / predictive values of mutations. These studies are carried out in a close collaboration with HOVON and other departments in the UMCG.
Mutational Evolution in Relapsed Diffuse Large B-Cell Lymphoma
Published in: Cancers
Access to document
10.3390/cancers10110459
document
Current genomic models in diffuse large B-cell lymphoma (DLBCL) are based on single tumor biopsies, which might underestimate heterogeneity. Data on mutational evolution largely remains unknown. An exploratory study using whole exome sequencing on paired (primary and relapse) formalin fixed paraffin embedded DLBCL biopsies (n = 14) of 6 patients was performed to globally assess the mutational evolution and to identify gene mutations specific for relapse samples from patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. A minority of the mutations detected in the primary sample (median...
Marcel Nijland, Annika Seitz, Martijn Terpstra, Gustaaf W van Imhoff, Philip M Kluin, Tom van Meerten, Çiğdem Atayar, Léon C van Kempen, Arjan Diepstra, Klaas Kok, Anke van den Berg
Lactate dehydrogenase levels and F-18-FDG PET/CT metrics differentiate between mediastinal Hodgkin’s lymphoma and primary mediastinal B-cell lymphoma
Published in: Nuclear Medicine Communications
Access to document
10.1097/MNM.0000000000000840
document
PURPOSE: This study aims to investigate whether clinical, laboratory, and fluorine-18-fluorodeoxyglucose (F-FDG) PET/CT findings can discriminate between mediastinal Hodgkin’s lymphoma and primary mediastinal B-cell lymphoma (PMBCL). PATIENTS AND METHODS: This retrospective study included 56 patients (42 with mediastinal Hodgkin’s lymphoma and 14 with PBMCL). Differences in clinical, laboratory, and F-FDG PET/CT metrics were assessed between Hodgkin’s lymphoma and PMBCL. RESULTS: Lactate dehydrogenase (LDH) and F-FDG PET/CT-based maximum tumor diameter, lesion-to-liver ratio maximum standardized uptake value (SUVmax), and lesion-to-liver ratio peak standardized uptake value (SUVpeak) were all significantly higher...
Rayan H M Alkhawtani, Walter Noordzij, Andor W J M Glaudemans, Rozemarijn S van Rijn, Hilde T van der Galiën, Hans Balink, Marcel Nijland, Hugo J A Adams, Gerwin Huls, Tom van Meerten, Thomas C Kwee
High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma
Published in: Blood
Access to document
10.1182/blood-2017-12-822817
document
Anne M R Schrader, Patty M Jansen, Rein Willemze, Maarten H Vermeer, Anne-Marie Cleton-Jansen, Sebastiaan F Somers, J H Hendrik Veelken, Ronald van Eijk, Willem Kraan, Marie José Kersten, Michiel van den Brand, Wendy B C Stevens, Daphne de Jong, Myrurgia Abdul Hamid, Bea C Tanis, Eduardus F M Posthuma, Marcel Nijland, Arjan Diepstra, Steven T Pals, Arjen H G ClevenJoost S P Vermaat
Combined PD-1 and JAK1/2 inhibition in refractory primary mediastinal B-cell lymphoma
Published in: Annals of Hematology
Access to document
10.1007/s00277-018-3233-9
document
Marcel Nijland, Tom van Meerten, Annika Seitz, Gerwin Huls, Robby Kibbelaar, Lydia Visser, Anke van den Berg, Arjan Diepstra
Combined loss of HLA I and HLA II expression is more common in the non-GCB type of diffuse large B cell lymphoma
Published in: Histopathology
Access to document
10.1111/his.13445
document
As an immune escape mechanism tumor cells may downregulate expression of Human Leukocyte Antigens (HLA). Loss of HLA class I and class II has been described in various subtypes of diffuse large B cell lymphoma (DLBCL), including the not otherwise specified (NOS) subgroup. 1,2 We analyzed HLA class I and class II expression in DLBCL not otherwise specified (NOS) to investigate whether there is an association between HLA expression, cell of origin (COO) and the recently reported FOXP1 expression in non-GCB DLBCL. 3 This article is protected by...